Summary of Prolo Pharmaceutical Conference Call Company Overview - Prolo Pharmaceutical is engaged in the CDMO (Contract Development and Manufacturing Organization) business, which is experiencing rapid growth due to capacity expansion and enhanced R&D capabilities. The company expects revenue growth to remain above 25% over the next three years, making it a core driver of performance [2][4][31]. Key Business Segments CDMO Business - The CDMO business is entering a phase of accelerated growth, supported by an increase in project numbers and commercial orders. Significant capital investments in advanced production facilities have been made, enhancing production efficiency and R&D capabilities [4][31]. - Revenue from the CDMO segment reached 1.884 billion yuan in 2024, with a compound annual growth rate (CAGR) exceeding 20% since 2020 [14]. API and Intermediate Business - Prolo has over 30 years of experience in the API (Active Pharmaceutical Ingredient) and intermediate business, with plans to add 30 to 50 new API products in the next three years. The company aims to expand into the medical beauty and cosmetics sectors [2][5]. - The company’s API projects include 116 ongoing projects, with 22 in the commercialization stage [20]. Formulation Business - The formulation segment has benefited from national procurement policies, leading to steady revenue growth of around 10% over the next three years. The company plans to develop 25 new formulation projects annually [6][30]. Financial Outlook - In 2025, Prolo's apparent revenue may be pressured by weak antibiotic demand and the clearing of raw material trading business, but profits are expected to remain stable or grow slightly. From 2026 onwards, revenue is projected to grow by about 10%, with profits increasing by over 20%, primarily driven by the CDMO business [7][32]. - The overall gross margin is expected to improve as the CDMO revenue share increases and cost-reduction measures are implemented [13][32]. Market Dynamics - The raw material and intermediate business is facing intense competition, but the company is diversifying its product matrix to mitigate cyclical impacts. The company is also leveraging advanced production capabilities to enhance competitiveness [8][26]. - In the veterinary medicine sector, Prolo's API business, particularly with florfenicol, is expected to benefit from a recovery in livestock farming and price stabilization [3][27][28]. Strategic Initiatives - Prolo's future strategy includes enriching its product matrix with new API products and expanding into high-margin markets such as medical beauty and cosmetics [29]. - The company has established a comprehensive supply chain for its formulation business, which includes over 120 formulation varieties across various therapeutic areas [30]. R&D and Innovation - Prolo is focusing on advanced research areas such as fluid chemistry, synthetic biology, and high-activity compounds, supported by a robust R&D team [17][18]. Conclusion - Prolo Pharmaceutical is positioned for significant growth in the coming years, driven by its CDMO business and strategic expansion into new markets. The company’s proactive approach to enhancing production capabilities and diversifying its product offerings is expected to yield positive financial results and improve overall profitability [2][32].

Core Viewpoint - The company has indicated that it offers medications that can treat viral infections such as influenza and bacterial infections, addressing concerns raised by investors regarding the current outbreak of diseases like chikungunya and influenza [2] Company Summary - The company, Prolo Pharmaceutical (000739.SZ), has stated that its products, including Oseltamivir and Amantadine, are effective against influenza viruses [2] - The company also provides a range of antibiotics such as Cefixime, Cefdinir, and Amoxicillin/Clavulanate Potassium for infection treatment [2]

Core Viewpoint - The company has completed the enrollment for the phase III clinical trials of its semaglutide project, which targets both weight loss and diabetes management, and is currently in the follow-up phase of administration [1] Group 1 - The semaglutide project includes indications for both weight loss and diabetes [1] - All participants have been enrolled in the phase III clinical trials [1] - The current stage of the project involves follow-up after administration [1]

金融界消息 截至2025年8月5日收盘，普洛药业（000739）报收于16.08元，下跌0.19%，换手率1.1%， 成交量12.71万手，成交金额2.04亿元。 普洛药业最新一期业绩显示，截至2025一季报，公司营业总收入27.30亿元、同比减少14.63%，归属净 利润2.49亿元，同比增长1.98%，扣非净利润2.06亿元，同比减少14.05%，流动比率1.505、速动比率 1.203、资产负债率44.93%。 通过天眼查大数据分析，普洛药业股份有限公司共对外投资了19家企业，参与招投标项目24次，知识产 权方面有商标信息125条，专利信息174条，此外企业还拥有行政许可7个。 来源：金融界 资金流向方面，今日主力资金净流出3385.00万元，占比成交额16.59%。其中，超大单净流出1908.74万 元、占成交额9.35%，大单净流出1476.26万元、占成交额7.23%，中单净流出流入1236.83万元、占成交 额6.06%，小单净流入2148.18万元、占成交额10.53%。 天眼查商业履历信息显示，普洛药业股份有限公司，成立于1997年，位于金华市，是一家以从事医药制 造业为主的企业。企业注册资 ...

Core Viewpoint - Pro Pharmaceutical announced the repurchase of 10,030,000 shares, representing 0.87% of its total share capital of 1,158,443,576 shares, as of July 31, 2025 [2] Summary by Category - **Company Actions** - The company has initiated a share repurchase program, acquiring a total of 10,030,000 shares through a dedicated repurchase account via centralized bidding [2] - **Share Capital Information** - The repurchased shares account for 0.87% of the company's total share capital, which stands at 1,158,443,576 shares [2]

格隆汇8月1日丨普洛药业(000739.SZ)公布，截至2025年7月31日，公司通过回购专用证券账户以集中竞 价交易方式累计回购公司股份10,030,000股，占公司目前总股本1,158,443,576股的0.87%，最高成交价为 14.82元/股，最低成交价为13.62元/股，成交总金额为1.44亿元(不含交易费用)。 ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-40 普洛药业股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 普洛药业股份有限公司（以下简称"公司"）于2025年2月19日召开第九届 董事会第十次会议审议通过了《关于回购公司股份方案的议案》，同意公司使用 自有资金以集中竞价交易方式回购公司部分股份，用于实施公司股权激励或员工 持股计划。本次回购股份价格不超过人民币22元/股（含），回购资金总额不低 于人民币7,500万元（含）且不超过人民币15,000万元（含）。具体回购股份数 量以回购期限届满或回购股份实施完毕时实际回购股份数量为准。回购期限为自 公司董事会审议通过回购股份方案之日起12个月内。具体内容详见公司分别于 2025 年 2 月 20 日 、 2025 年 2 月 21 日 在 《 证 券 时 报 》 和 巨 潮 资 讯 网 （http://www.cninfo.com.cn）上披露的《第九届董事会第十次会议决议公告》 （公告编号：2025-04）、《关于回购公司股份方案的公告》（公告编号： ...

证券代码：000739 证券简称：普洛药业 公告编号：2025-39 普洛药业股份有限公司 关于对下属公司担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、担保情况概述 1、2025 年 7 月 7 日，普洛药业股份有限公司（以下简称"公司"）与中国 银行股份有限公司东阳支行（以下简称"中国银行"）签订《保证合同》（合同 编号：横店 2025 人保字 115 号），同意为公司全资子公司浙江普洛家园药业有 限公司（以下简称"家园药业"）与中国银行签署的《流动资金借款合同》（合 同编号：横店 2025 人借字 115 号）中的 10,000 万元流动资金借款提供连带责任 保证，担保期限 12 个月。 2、2025 年 7 月 17 日，公司与中国农业银行股份有限公司东阳市支行（以 下简称"农业银行"）签订《保证合同》（合同编号：33100120250010398）， 同意为公司全资子公司家园药业与农业银行签署的《商业汇票银行承兑合同》（合 同编号：33180120250024671）中的 3,000 万元银行承兑汇票提供连带责任保证， 担保期限 ...

资金流向方面，今日主力资金净流出2544.07万元，占比成交额6.18%。其中，超大单净流出265.02万 元、占成交额0.64%，大单净流出2279.05万元、占成交额5.54%，中单净流出流入551.82万元、占成交 额1.34%，小单净流入1992.25万元、占成交额4.84%。 来源：金融界 普洛药业最新一期业绩显示，截至2025一季报，公司营业总收入27.30亿元、同比减少14.63%，归属净 利润2.49亿元，同比增长1.98%，扣非净利润2.06亿元，同比减少14.05%，流动比率1.505、速动比率 1.203、资产负债率44.93%。 金融界消息 截至2025年7月30日收盘，普洛药业（000739）报收于16.44元，下跌1.67%，换手率 2.15%，成交量24.94万手，成交金额4.11亿元。 通过天眼查大数据分析，普洛药业股份有限公司共对外投资了19家企业，参与招投标项目24次，知识产 权方面有商标信息125条，专利信息173条，此外企业还拥有行政许可7个。 天眼查商业履历信息显示，普洛药业股份有限公司，成立于1997年，位于金华市，是一家以从事医药制 造业为主的企业。企业注册资本1 ...

Core Points - Pro Pharmaceutical Co., Ltd. reported a stock price of 16.72 yuan, an increase of 4.17% as of July 29, 2025 [1] - The company experienced a total revenue of 2.73 billion yuan for Q1 2025, a year-on-year decrease of 14.63% [1] - Net profit attributable to shareholders was 249 million yuan, showing a year-on-year increase of 1.98% [1] Financial Performance - The company's operating revenue for Q1 2025 was 2.73 billion yuan, down 14.63% year-on-year [1] - Net profit for the same period was 249 million yuan, up 1.98% year-on-year [1] - The company's non-recurring net profit was 206 million yuan, a decrease of 14.05% year-on-year [1] - Current ratio stood at 1.505, quick ratio at 1.203, and debt-to-asset ratio at 44.93% [1] Investment and Business Activities - Pro Pharmaceutical has invested in 19 companies and participated in 24 bidding projects [2] - The company holds 125 trademark registrations and 173 patents [2] - Additionally, it possesses 7 administrative licenses [2] Company Background - Pro Pharmaceutical Co., Ltd. was established in 1997 and is located in Jinhua City [1] - The registered capital of the company is approximately 1.17 billion yuan, with paid-in capital of about 363 million yuan [1] - The legal representative of the company is Zhu Fangmeng [1]